Editor-in-Chief & Deputy Editor 2019-2021

 

Editor-in-Chief:

Nicolas LANTHIER

 

Deputy Editor:

Tim VANUYTSEL

 

 

Sponsors & Partners



Acta Gastroenterologica Belgica is supported by grants from its major sponsors

 

Acta Gastroenterologica Belgica is supported by grants

from its major sponsors

Dr Falk Pharma

 

 

 

 

 

 

Acta Gastro-Enterologica Belgica is published in

partnership with the following national societies


 

 

 

 

 

SRBGE

 

Medical treatment for peritoneal carcinomatosis from colorectal cancerMedical treatment of portal hypertension

Medical Treatment of Chronic Anal Fissure. Where do we stand on Reversible Chemical Sphincterotomy ?

Price: €10,00








Acta gastroenterol. belg., 2004, 67, 265-271

July-September Volume 67, fasc. 3

Medical Treatment of Chronic Anal Fissure. Where do we stand on Reversible Chemical Sphincterotomy ?

C. Van Kemseke, J. Belaiche - Department of Hepato-Gastroenterology, Centre Hospitalier Universitaire de Liège, Liège, Belgium.

Anal fissure is a common problem which can evolve to chronicity. Chronic anal fissure is thought to be an ischemic ulceration related to sphincter hypertonia. Lateral internal sphincterotomy, the most common treatment for chronic anal fissure, may cause permanent injury to anal sphincter leading to fecal incontinence. To avoid such side effect were developed medications producing a temporary or reversible sphincterotomy reducing the sphincter pressure only until the fissure has healed : nitrates, calcium channel antagonists and botulinum toxin. Authors aimed to summary the state of research on such treatments (efficacy, side effects, recurrence risk) and to clarify the role of these different medical options in the current treatment of chronic anal fissure.